Clinical Symptoms of Multiple Myeloma and their Validity in the Detection of symptomatic Progression and Relapse

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024789

Enrollment

500

Registered

2021-07-16

Start date

2021-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C90.0

Interventions

Group 1: Questionnaire

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients with newly diagnosed MM. 2. Adult patients with Multiple Myeloma treated at the University Hospital Freiburg irrespective of previous treatment (especially kind of drugs); first or second line treatment.

Exclusion criteria

Exclusion criteria: Underaged patients, patients without Multiple Myeloma, patients with known other malignancy

Design outcomes

Primary

Measure	Time frame
Differences of clinical symptoms in patients with stable disease and patients with symptomatic progression/relapse, respectively. Correlation of biochemical and/or radiographic progression and symptoms in MM-patients – Are clinical symptoms suitable for early detection of symptomatic progression/relapse? Assessment via questionnaire in our outpatient clinic during routine visits.	—

Secondary

Measure	Time frame
Clinical symptoms of MM at first MM-diagnosis Analysis of previous results in a larger cohort. Differences in clinical symptoms at first diagnosis and at symptomatic progression/relapse (questionnaire). Definition of clinical warning signs of MM and symptomatic progression/relapse.	—

Countries

Germany

Contacts

Public ContactLaura Wystrach

Universitätsklinik Freiburg

laura.wystrach@uniklinik-freiburg.de0761 270 24010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026